• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在少数存在隐匿性费城染色体重排的慢性髓性白血病患者中,会出现与BCR和ABL1断点相邻的缺失。

Deletions adjacent to BCR and ABL1 breakpoints occur in a substantial minority of chronic myeloid leukemia patients with masked Philadelphia rearrangements.

作者信息

De Melo Valeria A S, Milojkovic Dragana, Marin David, Apperley Jane F, Nacheva Elisabeth P, Reid Alistair G

机构信息

Department of Haematology, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, UK.

出版信息

Cancer Genet Cytogenet. 2008 Apr 15;182(2):111-5. doi: 10.1016/j.cancergencyto.2008.01.007.

DOI:10.1016/j.cancergencyto.2008.01.007
PMID:18406872
Abstract

Deletions at the t(9;22) breakpoint regions, found in 15% of chronic myeloid leukemia patients (CML) with an overt Philadelphia (Ph) translocation, are associated with an adverse disease prognosis in patients receiving interferon-alpha therapy. The incidence of deletions has been shown to vary for different cytogenetic subgroups of CML, with a significantly higher incidence of deletion in patients with a variant Ph translocation. To date, however, the frequency of such deletions in the subgroup of CML patients in whom the BCR/ABL1 fusion arises via submicroscopic chromosomal insertion (masked Ph) has not been investigated. We report the evaluation of 14 patients with masked Ph-positive CML for the presence of deletions extending 3' from BCR and 5' from ABL1 using two triple-color BCR/ABL probes. Deletions were identified in 3 patients (21%), encompassing sequences 5' to ABL1 in two of these and sequences 3' to BCR in the remaining patient, thus demonstrating that the phenomenon is a significant feature of the masked Ph CML subgroup. Furthermore, our findings are consistent with the notion that loss of genomic material is a potential side effect of any DNA breakage event at the 9q34.1 and 22q11.2 chromosomal regions, regardless of the subsequent mechanism of chromosomal rearrangement.

摘要

在15%具有明显费城(Ph)易位的慢性髓性白血病患者(CML)中发现的t(9;22)断点区域缺失,与接受α干扰素治疗的患者不良疾病预后相关。已表明缺失的发生率在CML的不同细胞遗传学亚组中有所不同,在具有变异Ph易位的患者中缺失发生率显著更高。然而,迄今为止,尚未研究通过亚显微染色体插入产生BCR/ABL1融合的CML患者亚组中此类缺失的频率。我们报告了使用两种三色BCR/ABL探针评估14例隐匿性Ph阳性CML患者是否存在从BCR 3'端和ABL1 5'端延伸的缺失。在3例患者(21%)中鉴定出缺失,其中2例包含ABL1 5'端的序列,其余1例包含BCR 3'端的序列,从而证明该现象是隐匿性Ph CML亚组的一个重要特征。此外,我们的发现与以下观点一致,即基因组物质的丢失是9q34.1和22q11.2染色体区域任何DNA断裂事件的潜在副作用,无论随后的染色体重排机制如何。

相似文献

1
Deletions adjacent to BCR and ABL1 breakpoints occur in a substantial minority of chronic myeloid leukemia patients with masked Philadelphia rearrangements.在少数存在隐匿性费城染色体重排的慢性髓性白血病患者中,会出现与BCR和ABL1断点相邻的缺失。
Cancer Genet Cytogenet. 2008 Apr 15;182(2):111-5. doi: 10.1016/j.cancergencyto.2008.01.007.
2
Mechanisms of genesis of variant translocation in chronic myeloid leukemia are not correlated with ABL1 or BCR deletion status or response to imatinib therapy.慢性髓性白血病中变异易位的发生机制与ABL1或BCR缺失状态或对伊马替尼治疗的反应无关。
Cancer Genet Cytogenet. 2008 Apr 15;182(2):95-102. doi: 10.1016/j.cancergencyto.2008.01.005.
3
Heterogenic molecular basis for loss of ABL1-BCR transcription: deletions in der(9)t(9;22) and variants of standard t(9;22) in BCR-ABL1-positive chronic myeloid leukemia.ABL1-BCR转录缺失的异质性分子基础:BCR-ABL1阳性慢性髓性白血病中der(9)t(9;22)的缺失及标准t(9;22)的变体
Genes Chromosomes Cancer. 2002 Jun;34(2):193-200. doi: 10.1002/gcc.10056.
4
Complex chromosome rearrangements may locate the bcr/abl fusion gene sites other than 22q11.复杂染色体重排可能会将bcr/abl融合基因位点定位在22q11以外的位置。
Haematologica. 2000 Jan;85(1):35-9.
5
Patterns of BCR/ABL gene rearrangements by interphase fluorescence in situ hybridization (FISH) in BCR/ABL+ leukemias: incidence and underlying genetic abnormalities.通过间期荧光原位杂交(FISH)检测BCR/ABL+白血病中BCR/ABL基因重排模式:发生率及潜在遗传异常
Leukemia. 2003 Jun;17(6):1124-9. doi: 10.1038/sj.leu.2402963.
6
Molecular cytogenetic characterization of deletions on der(9) in chronic myelocytic leukemia.慢性粒细胞白血病中9号衍生染色体缺失的分子细胞遗传学特征
Cancer Genet Cytogenet. 2006 Jun;167(2):97-102. doi: 10.1016/j.cancergencyto.2006.01.011.
7
Molecular cytogenetic characterization of variant Philadelphia translocations in chronic myeloid leukemia: genesis and deletion of derivative chromosome 9.慢性髓性白血病中变异型费城染色体易位的分子细胞遗传学特征:衍生9号染色体的起源与缺失
Cancer Genet Cytogenet. 2009 Oct;194(1):30-7. doi: 10.1016/j.cancergencyto.2009.05.010.
8
Complex variant Philadelphia translocations involving the short arm of chromosome 6 in chronic myeloid leukemia.慢性髓性白血病中涉及6号染色体短臂的复杂变异型费城染色体易位
Haematologica. 2002 Feb;87(2):143-7.
9
Deletion size characterization of der(9) deletions in Philadelphia-positive chronic myeloid leukemia.费城染色体阳性慢性髓性白血病中9号衍生染色体(der(9))缺失的缺失大小特征分析
Cancer Genet Cytogenet. 2006 Oct 15;170(2):89-92. doi: 10.1016/j.cancergencyto.2006.06.006.
10
A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression.应用间期荧光原位杂交技术对慢性髓性白血病9号衍生染色体上ABL基因缺失发生率及其与疾病进展关系的研究
Genes Chromosomes Cancer. 2003 Jul;37(3):291-9. doi: 10.1002/gcc.10197.

引用本文的文献

1
BCR/ABL1 fluorescence hybridization fusion signals on both copies of chromosome 22 in a Philadelphia-masked chronic myeloid leukemia case: implication for the therapy.费城染色体隐匿型慢性髓性白血病病例中22号染色体两个拷贝上的BCR/ABL1荧光原位杂交融合信号:对治疗的意义
Hematol Rep. 2021 Mar 24;13(1):8795. doi: 10.4081/hr.2021.8795. eCollection 2021 Mar 5.
2
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy.隐匿性BCR-ABL融合基因作为慢性髓性白血病的变异重排:分子细胞遗传学特征及其对酪氨酸激酶抑制剂治疗的影响
Oncotarget. 2017 May 2;8(18):29906-29913. doi: 10.18632/oncotarget.15369.
3
Standard and variant Philadelphia translocation in a CML patient with different sensitivity to imatinib therapy.
一名对伊马替尼治疗敏感性不同的慢性粒细胞白血病患者的标准型和变异型费城染色体易位
Leuk Res Rep. 2013 Aug 31;2(2):75-8. doi: 10.1016/j.lrr.2013.07.004. eCollection 2013.
4
Imatinib failure and response to dasatinib in a patient with chronic myeloid leukemia in blast crisis and a novel, nine-nucleotide BCR-ABL insertion mutation.一名处于急变期的慢性髓性白血病患者对伊马替尼耐药而对达沙替尼敏感,并存在一种新型的9个核苷酸的BCR-ABL插入突变
Blood Cancer J. 2013 Mar 8;3(3):e104. doi: 10.1038/bcj.2013.3.
5
Molecular cytogenetic characterization of Philadelphia-negative rearrangements in chronic myeloid leukemia patients.慢性髓性白血病患者费城阴性重排的分子细胞遗传学特征。
J Cancer Res Clin Oncol. 2011 Sep;137(9):1329-36. doi: 10.1007/s00432-011-1002-4. Epub 2011 Jul 8.
6
Array comparative genomic hybridization detects chromosomal abnormalities in hematological cancers that are not detected by conventional cytogenetics.阵列比较基因组杂交检测到了常规细胞遗传学检测不到的血液系统恶性肿瘤中的染色体异常。
J Mol Diagn. 2010 Sep;12(5):670-9. doi: 10.2353/jmoldx.2010.090192. Epub 2010 Aug 19.
7
Non random distribution of genomic features in breakpoint regions involved in chronic myeloid leukemia cases with variant t(9;22) or additional chromosomal rearrangements.在涉及变异 t(9;22)或其他染色体重排的慢性髓性白血病病例中,断裂点区域的基因组特征呈非随机分布。
Mol Cancer. 2010 May 25;9:120. doi: 10.1186/1476-4598-9-120.
8
Persistence of derivative chromosome 22 after achieving a major molecular response in chronic myeloid leukemia with a cryptic BCR-ABL1 fusion gene.慢性髓性白血病中隐匿性 BCR-ABL1 融合基因导致达到主要分子缓解后衍生染色体 22 的持续存在。
Int J Hematol. 2009 Dec;90(5):623-626. doi: 10.1007/s12185-009-0448-5. Epub 2009 Dec 10.
9
FISH mapping of Philadelphia negative BCR/ABL1 positive CML.费城阴性BCR/ABL1阳性慢性粒细胞白血病的荧光原位杂交定位
Mol Cytogenet. 2008 Jul 18;1:14. doi: 10.1186/1755-8166-1-14.